Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

PureTech Health’s ESMO Presentation Puts LYT-200 Clinical Evidence in the Spotlight

PureTech Health (LSE:PRTC) is attracting attention because of its latest corporate or operating update.

Ankur Sharma | 19 October 2026

TheraCryf Reaches an Ox-1 Research Milestone as Investors Watch the Route to Clinical Development (LSE:TCF)

TheraCryf said its Ox-1 preclinical data package is complete, marking a development milestone for its research programme. Investors will focus on what the package demonstrates, whether any additional studies or regulatory work are required, and how the company plans to finance the next stages. …

Ankur Sharma | 19 October 2026

Tristel’s Results Show Double-Digit Growth as Investors Track US Expansion and New Products (LSE:TSTL)

Tristel reported FY2026 revenue of £51.1 million, up 10%, adjusted profit before tax of £11.7 million, up 15%, and cash plus short-term investments of £16.0 million. Gross margin rose to 82%, and the full-year dividend increased 5% to 14.91p per share. Growth reflected its …

Ankur Sharma | 19 October 2026

CVS Group’s Buyback Puts Veterinary Demand and Practice-Level Margins Back in Focus (LSE:CVSG)

CVS Group’s own-share transaction invites scrutiny of capital allocation at a veterinary services business. Investors will look at organic revenue growth, client visits, pricing, vet and nurse recruitment, wage inflation, practice utilisation and integration of acquired clinics. Pet-care demand can be resilient, but affordability …

Ankur Sharma | 19 October 2026

GSK’s Cancer Pipeline Gets a Fresh Catalyst as Ris-Rez Shows Early Lung Cancer Activity

The key issue is whether the announced development translates into measurable financial or operational progress.

Ankur Sharma | 19 October 2026

Hemogenyx’s Nitto Agreement Raises Interest in an In-Vivo CAR-T Delivery Approach (LSE:HEMO)

Hemogenyx Pharmaceuticals has entered a feasibility-study agreement with Japan-based Nitto Denko to evaluate targeted lipid-nanoparticle delivery of Hemogenyx’s CAR messenger RNA. The work explores a potential route toward an off-the-shelf, in-vivo CAR-T therapy. Investors will watch the study design, delivery efficiency, targeting specificity, safety …

Ankur Sharma | 19 October 2026

Why Cizzle Biotechnology’s Award Shortlisting Puts Its Lung-Cancer Test in Focus (LSE:CIZ)

• Cizzle Biotechnology Holdings (LSE:CIZ) is in focus following an update on shortlisted for one nucleus award 2026.• The announcement is relevant to industry recognition and visibility.• The next assessment should focus on implementation, financial consequences and management’s follow-through.• The headline alone does not …

Ankur Sharma | 19 October 2026

ESMO Countdown Puts Avacta Group PLC (LSE:AVCT) Back in the FTSE AIM All-Share Biotech Spotlight

The stock has also been working through the effects of a fundraise completed at the start of October. After the placing was priced at a modest discount, the shares have traded in the mid to high 60 pence range. The most recent session showed …

Ankur Sharma | 19 October 2026

Bottom-Fishing or Value Trap? Craneware plc (LSE:CRW) Fights to Steady in the FTSE AIM 100 After Reset

The only formal update on 15 October was a routine block admission return confirming no new shares were issued under employee schemes. The real debate is whether September's heavy fall has already priced in the bad news.

Ankur Sharma | 19 October 2026

Oxford Nanopore (LSE:ONT) Sinks to Bottom of FTSE 250 as Tech Sell-Off and Profit-Taking Bite

There was no fresh trading update or regulatory filing to explain the fall. Instead, market commentators linked it to the rotation that dominated the week. A global sell-off in AI and semiconductor stocks, triggered by fears of competition in memory chips and hot US …

Ankur Sharma | 19 October 2026
Support

Hi! How can we help you today?

Loading…